The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
Opinion|Videos|April 17, 2025
Every Check Counts: Cases of AI-Assisted Skin Cancer Detection
Author(s)Kevin Wong, MD
Advertisement
Advertisement
Related to this article
The proportion of US women aged 21 to 29 years who have never received cervical cancer screening more than doubled between 2005 and 2023, according to new data.
Stepped reminders to PCPs and patients increased annual lung cancer screening adherence by 27.7 percentage points, according to new research.
Advertisement
Advertisement
Trending on Patient Care Online
1
Beyond Semaglutide and Tirzepatide: The Next Wave of Obesity Medicines
2
FDA Grants Priority Review to Elinzanetant for VMS in HR+ Breast Cancer Patients on Endocrine Therapy
3
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
4
FDA Expands Baricitinib Approval to Adolescents With Severe Alopecia Areata
5